Monographie - Oxaliplatin

Viimeisin päivitys :
19/11/2024

Oxaliplatin

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	Saksa
Bendaplatin	Saksa
Bioezulen	Brasilia
Celdach	Marokko
Crisapla	Chile, Ecuador, Venezuela
Crisatinox	Turkki
Dabenzol	Argentiina, Ecuador
Dacplat	Argentiina
Eloxarin	Ecuador
Eloxatin	Belgia, Brasilia, Chile, Egypti, Espanja, Iran, Iso-Britannia, Italia, Itävalta, Kolumbia, Luxemburg, Malesia, Marokko, Meksiko, New Zealand, Norja, Portugali, Romania, Ruotsi, Sveitsi, Thaimaa, Turkki, Venezuela, Yhdistyneet arabiemiirikunnat, Yhdysvallat
Eloxatine	Marokko, Ranska, Sveitsi
Entia	Kolumbia, Meksiko
Euroxaliplatine	Saksa
Glenoxal	Marokko
Goxyral	Argentiina, Ecuador
Kebir	Argentiina, Marokko
Linoxa	Turkki
Lisix	Chile
Metaplatin	Argentiina
Oliptino	Argentiina
Onicol	Chile, Marokko
Oxalibbs	Brasilia
Oxaliplan	Saksa
Riboxatin	Saksa

Viitteet : Oxaliplatin

	tyyppi	julkaisu
1662	Lehti	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Lehti	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Lehti	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Lehti	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Lehti	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Laboratorio	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Laboratorio	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Lehti	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Lehti	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Lehti	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Laboratorio	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Lehti	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Laboratorio	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Laboratorio	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Lehti	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Lehti	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Lehti	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales